Last update 01 Nov 2024

Lower Urinary Tract Symptoms

Last update 01 Nov 2024

Basic Info

Synonyms

LUTS - Lower urinary tract symptoms, Lower Urinary Tract Symptom, Lower Urinary Tract Symptoms

+ [8]

Introduction

Symptoms of disorders of the lower urinary tract including frequency, NOCTURIA; urgency, incomplete voiding, and URINARY INCONTINENCE. They are often associated with OVERACTIVE BLADDER; URINARY INCOMPETENCE; and INTERSTITIAL CYSTITIS. Lower urinary tract symptoms in males were traditionally called PROSTATISM.

Drugs associated with Lower Urinary Tract Symptoms

Solifenacin Succinate/Tamsulosin Hydrochloride

Target

M3 receptor x α1A-AR

Mechanism

M3 receptor antagonists [+1]

Active Org.

Astellas Pharma, Inc.

Originator Org.

Astellas Pharma, Inc.

Active Indication

Lower Urinary Tract Symptoms

Inactive Indication

Dysuria [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date07 Oct 2013

Mirabegron

Target

GP IIb/IIIa

Mechanism

GP IIb/IIIa antagonists

Active Org.

Astellas Pharma Global Development, Inc. [+3]

Originator Org.

Astellas Pharma, Inc.

Active Indication

Neurogenic detrusor overactivity [+2]

Inactive Indication

Cyanosis and Hepatic Disease [+7]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jul 2011

Degarelix Acetate

Target

GnRHR

Mechanism

GnRHR antagonists

Active Org.

Ferring Pharmaceuticals A/S [+5]

Originator Org.

Ferring BV

Active Indication

Castration-sensitive prostate cancer [+5]

Inactive Indication

Advanced Prostate Carcinoma [+6]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date24 Dec 2008

631

Clinical Trials associated with Lower Urinary Tract Symptoms

NCT06273098 / WithdrawnNot ApplicableIIT

Understanding and Enhancing Schoolchildren's Bathroom Habits: Uncovering Barriers and Promoting Healthy Bladder Habits

The aim of this study is to promote healthy bladder behaviors among school children. We hypothesize that a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies can promote healthy bladder behaviors among school children.

Start Date01 Jan 2028

Sponsor / Collaborator

Stanford University

NCT06546735 / Not yet recruitingPhase 3

Randomized, Double-blind, Double-masked, Parallel-group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.

The clinical trial to evaluate the fixed-dose combination (N0728), with the aim of providing the Brazilian market with an alternative, potentially effective, safe and convenient therapeutic approach for the treatment of Lower Urinary Tract Symptoms (LUTS) in men with Benign Prostatic Hyperplasia (BPH). The fixed-dose combination has synergistic action between drugs from different classes and offers significant potential advantages, such as better adherence to treatment. The trial will assess the non-inferiority in efficacy and safety of the proposed fixed-dose combination compared to alpha-adrenergic antagonists.

Start Date30 Nov 2026

Sponsor / Collaborator

Eurofarma Laboratórios SA

NCT06336564 / Not yet recruitingNot ApplicableIIT

Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause: Randomized Clinical Trial

Genitourinary Syndrome fo Menopause (GSM) is made up of a set of changes in the region of the vulva, vagina and lower urinary tract associated with a decrease in estrogen levels in the urogenital tissue, which leads to a reduction in blood supply, disorders in collagen metabolism and skin elasticity. The standard treatment for urinary incontinence during menopause is pelvic floor muscle training, associated or not with local hormone replacement therapy. Although low cost and easy to access, it is associated with low patient's adherence. Physical methods such as laser and radiofrequency in non-ablative, ablative and microablative forms are technologies that have recently been used in the vaginal mucosa to promote neoelastogenesis and neocollagenesis. It is hypothesized that menopausal women, who present symptoms of GSM, may benefit from this new, minimally invasive resource (microablative radiofrequency). This is a randomized clinical trial in which women aged between 40 and 65 years old will be included with clinical complaints of urinary symptoms associated with GSM. A basic anamnestic questionnaire will be used as the study instrument to collect sociodemographic, clinical data and symptoms, following the routine and standard of the service. To evaluate the treatment, the following will be used: voiding diary, pad test, vaginal cytology, histopathology, Female Sexual Function Index (FSFI), Short-Form Health Survey - SF-36 Questionnaire, King's Health Questionnaire, evolution of symptoms (dryness, pain during sexual activity, vaginal laxity, itching, burning sensation and pain in the vaginal introitus) and level of patient's satisfaction. Patients will be randomized into: group 1 or control group, which will perform pelvic floor muscle training, PFMT, with supervision (three times) and at home twice a day, and group 2 or test group, which will perform the same PFMT protocol associated with vaginal microablative radiofrequency. 10% lidocaine spray will be applied three minutes before the procedure and three applications will be made to the vagina/vaginal introitus, with an interval of 30 to 40 days. The purpose of this study is to test the efficacy and duration of effect of microablative radiofrequency in the treatment of urinary symptoms associated with GSM.

Start Date01 Aug 2025

Sponsor / Collaborator-

100 Clinical Results associated with Lower Urinary Tract Symptoms

100 Translational Medicine associated with Lower Urinary Tract Symptoms

0 Patents (Medical) associated with Lower Urinary Tract Symptoms

13,925

Literatures (Medical) associated with Lower Urinary Tract Symptoms

01 Dec 2025·Current Urology Reports

Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia

Review

Author: Chughtai, Bilal ; Bhojani, Naeem ; Codelia-Anjum, Alia ; Winograd, Joshua ; Elterman, Dean ; Lama, John ; Zorn, Kevin C

PURPOSE OF REVIEWThe prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.RECENT FINDINGSThe dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs. Additionally, use of iTiND, along with recent advancements in temporary (EXIME, Prodeon Urocross) and permanent (Zenflow Spring, Butterfly, and ClearRing) stent designs, have demonstrated rapid, lasting, and low-cost LUTS relief with sustained sexual function. Minimally invasive solutions that offer in-office treatment, rapid symptom relief, shorter recovery times, and preservation of sexual function hold great promise in improving outcomes in managing BPH patients with LUTS.

01 Jan 2025·Journal of Affective Disorders

Bidirectional relationships between depression, anxiety and urinary symptoms in women: A prospective cohort study

Article

Author: Fraser, Abigail ; Tilling, Kate ; Drake, Marcus J ; Heron, Jon ; Drake, Marcus J. ; Joinson, Carol

OBJECTIVESTo examine (i) if depression and anxiety are prospectively associated with subsequent lower urinary tract symptoms (LUTS) and (ii) if LUTS are prospectively associated with subsequent depression.PARTICIPANTS AND METHODSThe study is based on data from parous middle-aged women from the Avon Longitudinal Study of Parents and Children. LUTS were assessed using the Bristol Female LUTS Questionnaire and the International Consultation on Incontinence Questionnaire on Female LUTS. Depression was assessed using the Edinburgh Postnatal Depression Scale and anxiety was assessed using the Crown Crisp Experiential Index. We used multivariable logistic regression to examine (i) associations between depression and anxiety at baseline in 2002-04 and subsequent LUTS at follow-up in 2011-2012 (n = 5291) and (ii) associations between LUTS at baseline in 2002-04 and subsequent depression at follow-up in 2010-11 (n = 6147). Analyses were adjusted for age, socioeconomic factors, stressful life events, social support, smoking, weekly alcohol consumption, BMI, physical activity, obstetric/reproductive factors, and menopausal status.RESULTSWe found evidence of prospective associations between depression and subsequent mixed urinary incontinence [odds ratio = 1.97, 95 % confidence interval = 1.16, 3.33], any urinary incontinence [1.68 (1.21, 2.31)], and urgency [1.90 (1.28, 2.83)]. Anxiety was only associated with subsequent nocturia [1.84 (1.04, 3.26)]. Only stress urinary incontinence was associated with subsequent depression [1.37 (1.03, 1.83)].CONCLUSIONSWe find evidence that mental health problems could be contributing factors, as well as consequences, of LUTS. Research is needed to determine if these observed associations are causal and to identify underlying mechanisms.

01 Dec 2024·Journal of Affective Disorders

LUTS/BPH increases the risk of depressive symptoms among elderly adults: A 5-year longitudinal evidence from CHARLS

Article

Author: Ding, Zehua ; Su, Dongyu ; Xu, Kexin ; Wang, Huanrui ; Peng, Yu ; Zhang, Weiyu ; Sun, Yiran ; Ke, Hanwei ; Wang, Qi

OBJECTIVEThe prevalence of Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) is notably high and potentially elevates the likelihood of depressive symptoms. This study was designed to employ both cross-sectional and longitudinal methodologies to explore the correlation between LUTS/BPH and depressive symptoms among middle-aged and elderly men in China.METHODSThis investigation utilized data from the China Health and Retirement Longitudinal Study (CHARLS), with the initial dataset from 2015 serving as the baseline and subsequent data from 2018 and 2020 facilitating longitudinal analysis. The study encompassed a baseline cohort of 5156 men aged 45 years and above, and an expansive longitudinal analytical sample of 23,530 participants spanning from 2015 to 2020. The assessment of depressive symptoms was conducted using the 10-item Center for Epidemiological Studies Depressive Symptoms Scale (CESD-10). To investigate the factors associated with LUTS/BPH, the relationship between LUTS/BPH and depressive symptoms, and to evaluate the incidence rate of depressive symptoms onset based on LUTS/BPH status, multivariate logistic analyses and logistic regression models were employed.RESULTSOur results reveal a markedly higher incidence of depressive symptoms among individuals with LUTS/BPH, at 30.16 %, compared to 22.94 % in those without LUTS/BPH. This pattern was consistent in both mild and moderate depressive symptoms categories. However, the prevalence of severe depressive symptoms did not exhibit a significant disparity between the two groups. Longitudinal analysis spanning from 2015 through 2018 and 2020 further corroborated these observations. Individuals with LUTS/BPH showed a substantially higher incidence of depressive symptoms across all severity levels compared to those without LUTS/BPH. Specifically, the presence of LUTS/BPH was linked to a 53 % heightened risk of mild depressive symptoms, a 45 % increase in moderate depressive symptoms, and an alarming 229 % surge in severe depressive symptoms risk between 2015 and 2018. Additionally, from 2015 to 2020, there was a 30 % increased risk for mild depressive symptoms, a 41 % rise for moderate depressive symptoms, and a 106 % escalation in the risk of severe depressive symptoms among those with LUTS/BPH.CONCLUSIONIn middle-aged and older Chinese adults, LUTS/BPH were correlated with an elevated risk of depressive symptoms.

118

News (Medical) associated with Lower Urinary Tract Symptoms

30 Oct 2024

·www.globenewswire.com

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company’s common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions. BofA Securities, Piper Sandler and Morgan Stanley are acting as joint book-running managers for the proposed offering. The securities are being offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 1, 2023. This offering is being made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement. A preliminary prospectus supplement related to the offering (including the accompanying prospectus) has been filed with the SEC and is available on the SEC’s website located at www.sec.gov. A final prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the SEC. Copies of the preliminary prospectus supplement and the final prospectus supplement, when available, and the accompanying prospectus may also be obtained, from BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attn: Prospectus Department, or via email: dg.prospectus_requests@bofa.com; from Piper Sandler, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or via e-mail at prospectus@psc.com; and from Morgan Stanley, Prospectus Department, 180 Varick Street, New York, New York 10014, or email: prospectus@morganstanley.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About PROCEPT BioRobotics CorporationPROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Forward Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation statements regarding the expected closing of the public offering are forward-looking statements reflecting the current beliefs and expectations of PROCEPT BioRobotics’ management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent PROCEPT BioRobotics’ current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including market interest rates, the trading price and volatility of PROCEPT BioRobotics’ common stock, and risks relating to PROCEPT BioRobotics’ business, including those risks described in periodic reports that PROCEPT BioRobotics files from time to time with the SEC, as well as the preliminary prospectus supplement and accompanying prospectus relating to the offering. The forward-looking statements included in this press release speak only as of the date of this press release, and PROCEPT BioRobotics does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law. Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@procept-biorobotics.com

28 Oct 2024

·www.prnewswire.com

Optilume® BPH Catheter System Issued Category 1 CPT Code by American Medical Association

PORTSMOUTH, N.H., Oct. 28, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp (Laborie), announced today that the American Medical Association (AMA) has issued the new Category 1 Current Procedural Terminology (CPT®) code 52XX2 to report cystourethroscopy, with initial transurethral anterior prostate commissurotomy. The new code is applicable to services that physicians perform with Laborie's Optilume® BPH Catheter System, a minimally invasive surgical therapy (MIST) that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for treating lower urinary tract symptoms (LUTS) secondary to BPH. Optilume BPH has the highest Qmax in BPH MIST clinical trials to date (19mL/sec at 2 years) and revolutionizes the treatment paradigm by providing immediate and durable symptom relief along with quick recovery time for men experiencing BPH-induced LUTS. The technology was developed in response to patient and physician dissatisfaction with current treatment options. "This is a significant milestone for Optilume BPH, and we welcome the AMA Editorial Panel's decision," said Michael Frazzette, Laborie's President and CEO. "The new code will broaden patient access by establishing a reimbursement pathway for this important treatment and will help enable adoption at various sites of care." Beginning January 1, 2026, providers can report the new CPT code for Optilume BPH. Created and maintained by the AMA, CPT codes are widely recognized and used to describe healthcare services and procedures to facilitate reimbursement by public and private health insurance providers in the United States. About Laborie Medical Technologies Headquartered in Portsmouth, New Hampshire, Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class clinical education & information program. Laborie is a portfolio company of Patricia Industries. For more information visit  . SOURCE Laborie Medical Technologies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Oct 2024

·www.prnewswire.com

Bright Uro adds two industry pioneers to its Board of Directors

Martha Goldberg Aronson and Dr. Sanford Siegel to provide leadership and guidance for upcoming product launch IRVINE, Calif., Oct. 17, 2024 /PRNewswire/ -- Bright Uro, a medical device company with a mission to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, today announced the addition of two industry pioneers to its Board of Directors. Martha Goldberg Aronson, a 25-year industry veteran, joins the board as a Director, and Sanford Siegel, MD brings decades of urology and practice leadership experience to his new role as Board Advisor. Ms. Goldberg Aronson, currently Lead Independent Director for ConMed Corporation, has held executive leadership roles at Ecolab, Hill-Rom and Medtronic. She led the Medtronic business that launched the highly successful InterStim sacral neuromodulation device. Dr. Siegel is the former CEO and Board Director at United Urology Group and was the founder and CEO of Chesapeake Urology Associates. "I am excited to help Bright Uro achieve their vision by drawing on the experiences I've gained from working in the urology field along with Board roles throughout my career," said Ms. Goldberg Aronson. "The company's transformative product Glean represents a paradigm shift for the field and I believe in this world class team of passionate and committed professionals." "Urodynamic diagnostic technology has advanced very little over the past 40 years and Glean is the first product I've seen that has the potential to revolutionize the field. Glean has the potential to remove many of the barriers to urodynamic testing that exist with legacy technologies," said Dr. Siegel, who is currently serving on the board of MDxHealth. "I truly believe it will increase access to care for patients and make it easy for clinicians to perform high-quality urodynamic studies, and I'm proud to join this effort." "I am so grateful to have such accomplished and experienced additions to our Board," said Derek Herrera, founder and CEO of Bright Uro. "Martha and Dr. Siegel are both innovators and pioneers who have earned the highest respect in their fields. Their leadership and insight will be invaluable as we prepare to launch the Glean Urodynamics System in 2025." About Bright Uro Based in Irvine, Calif., Bright Uro's mission is to transform care of lower urinary tract symptoms (LUTS) with its innovative technology that is poised to disrupt outdated urodynamics approaches. The Company's investigational Glean™ Urodynamics System is designed to enable wireless, catheter-free urodynamics monitoring, with the ultimate goal of improving patient comfort and clinical outcomes. For more information, visit . SOURCE Bright Uro WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive Change

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lower Urinary Tract Symptoms

Basic Info

Related

Analysis